Fluorouracil News and Research

RSS

Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.

Addition of gemcitabine to standard postoperative treatment increased pancreatic cancer patients' survival by 50 percent

Adding the cancer-fighting drug gemcitabine to standard therapy after surgery significantly improves survival for patients with the most common form of pancreatic cancer, according to a new multicenter study led by a University of Maryland radiation oncologist.

6 Jun 2006

Taxotere combined with standard chemotherapy improves survival in advanced head and neck cancers

The addition of docetaxel (Taxotere) to an initial chemotherapy regimen for inoperable head and neck cancers reduced mortality by nearly 30 percent over three years following treatment compared to the standard two-drug combination.

5 Jun 2006

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

Patients and their physicians should be careful when selecting a chemotherapy drug to treat colorectal cancer that has spread to the liver, say researchers at The University of Texas M. D. Anderson Cancer Center in Houston.

3 May 2006

Studying the gene-expression profiles of patients with colorectal cancer might help predict their response to chemotherapy

Studying the gene-expression profiles of patients with colorectal cancer might help predict their response to chemotherapy.

15 Mar 2006

Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer

A new study shows that patients whose colorectal cancer has spread to the liver who received an approach called hepatic arterial infusion (HAI) - the administration of chemotherapy directly to the liver through a pump in the abdomen - fare better than those who received traditional, intravenous chemotherapy.

1 Mar 2006

Mangafodipir appears to increase the cancer-killing ability of some chemotherapy drugs

A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.

21 Feb 2006

FOLFOX now treatment standard for colorectal cancer in the United States

One of the newest and most potent chemotherapies for colon cancer is as safe and effective for the elderly as it is for younger patients, based on a University of North Carolina at Chapel Hill-led data review.

16 Feb 2006

Chemotherapy is a beneficial treatment women and elderly

Although all eligible patients with stage III colon cancer should be offered adjuvant chemotherapy treatment because it improves survival, up to one-third are not, and many of these excluded patients are women and the elderly, say researchers who looked at data from more than 85,000 patients.

7 Dec 2005

Expert highlights public health problem posed by colorectal cancer

Colorectal cancer is a significant public health problem for which differing treatment regimes hold different benefits in associated efficacy, safety and tolerability, according to study findings showcased at the 13th European Cancer Conference (ECCO).

3 Nov 2005

Imiquimod and fluorouracil emerge as effective weapons for treating superficial basal cell carcinomas

Basal cell carcinoma, a type of skin cancer, affects millions of people worldwide. While traditional treatment has been surgery and radiation, topical treatments in combination with surgery are showing more promise for patients with basal cell carcinoma.

21 Jul 2005

Chemotherapy options improve for patients with advanced colorectal cancer

For the first time, researchers have shown that a chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) is as safe and effective as infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) in the first-line treatment of metastatic colorectal carcinoma (MCRC).

6 Jun 2005

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Final results from the largest international study in the treatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere, cisplatin and 5-fluorouracil) had significantly improved overall survival rates compared to patients who received a standard treatment (cisplatin and 5- fluorouracil).

16 May 2005

A combination of chemotherapy drugs could double survival rates for pancreatic cancer

Pancreatic cancer has a poor prognosis. More than 80% of patients present with advanced disease at diagnosis, and mortality is high. A single chemotherapy drug, gemcitabine, is regarded as the standard treatment, but it has lead to a 1-year overall survival of only 17—28% in clinical trials.

9 May 2005

Herceptin - more powerful treatment for patients with HER-2-positive breast cancer

A new use of the drug Herceptin appears to offer a much more powerful treatment advantage than expected for patients with HER-2-positive breast cancer, say researchers at The University of Texas M. D. Anderson Cancer Center.

29 Mar 2005

New cancer drug Avastin keeps cancer under control

Data published for the first time today in the leading Journal of Clinical Oncology showed that the unique new cancer drug Avastin keeps cancer under control for a significantly longer duration, even when used in a group of elderly patients with advanced colorectal cancer who are too sick to tolerate traditional aggressive chemotherapy.

1 Mar 2005

Avastin available across Europe within the next few weeks

Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer.

16 Jan 2005

Study finds new method can improve chemo survival

Seeking to find a way to lessen patients’ vulnerability to deadly infections following chemotherapy, researchers at the Stanford University School of Medicine have figured out a way to boost the immune function in animals following such treatments.

21 Dec 2004

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Genentech and Roche today announced that a randomized Phase III study of Avastin™ (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival.

29 Nov 2004

Genentech announces FDA approval of Avastin manufacturing

Genentech has announced that the U.S. Food and Drug Administration approved the supplemental Biologics License Application (sBLA) for the manufacturing of Avastin™ (bevacizumab) bulk drug substance at the company's facility in Vacaville, California.

11 Aug 2004

New screening technique to look for genes that change patients' responses to cancer drugs and other medications

Scientists have developed a new screening technique to help them look for genes that change patients' responses to cancer drugs and other medications.

3 Aug 2004